Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors

NCT05904236 is registered in ClinicalTrials.gov with IconOVir Bio as lead sponsor.

NCT NCT05904236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05904236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 First-in-Human Dose Escalation and Expansion Study to Assess Safety and Tolerability of Intravenous Administration of ICVB-1042 in Patients With Advanced Solid Tumors
Lead sponsor
IconOVir Bio
Phase
Phase 1
Overall status
Terminated
Start date
June 1, 2023
Completion date
December 20, 2024
Enrollment
17 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

patients with advanced solid tumors